A Phase 2 Clinical Study: Efficacy and Safety of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation
Phase of Trial: Phase II
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Pyrotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 27 Mar 2017 Status changed from not yet recruiting to recruiting.
- 19 Jul 2016 New trial record